Asterias Bio gets $14.3M award from CIRM


BioTime (BTX +7.3%) subsidiary Asterias Biotherapeutics receives a $14.3M strategic partnership award from the California Institute for Regenerative Medicine (CIRM). The award supports the company's Phase 1/2 dose escalation trial of AST-OPC1 in cervical spinal cord injury.

Comments (1)
  • California Stem Cell Report
    , contributor
    Comments (3) | Send Message
     
    You would have read this news about Biotime on May 22 instead of May 30 if you followed the California Stem Cell Report... californiastemcellrepo...
    3 Jun 2014, 12:14 AM Reply Like
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs